P-1416. Preference for Long-acting Injectable Tuberculosis Preventive Treatment over Oral TB Preventive Therapy among Healthcare Workers
Victoria Ontiveros, Zaza Avaliani, Luka Khelaia, Papuna Papuashvili, Ruth Demissie, Dzigbordi Kamasa-Quashie, A Nichole Evans, Angie Campbell, Naira Chanukvadze, Nelly Solomonia, Natalia Tsereteli, Tekla Madzgharashvili, Lauren F Collins, Russell R Kempker, Maia Kipiani

TL;DR
Healthcare workers in a high TB burden area show a moderate preference for long-acting injectable TB preventive treatment over oral therapy, with concerns about safety and efficacy.
Contribution
This study evaluates healthcare workers' acceptability of long-acting injectable TB preventive treatment in a high TB burden setting.
Findings
52% of healthcare workers favored long-acting injectable TB preventive treatment over oral therapy.
Majority preferred a single-injection regimen, but concerns about side effects and efficacy were reported.
Acceptability was not significantly influenced by age or occupation, but beliefs about TPT effectiveness were associated with preference.
Abstract
Suboptimal adherence to daily/weekly oral tuberculosis preventive treatment (TPT) regimens among tuberculosis (TB) contacts poses a challenge to TB infection management. Long-acting injectable (LAI) formulations of TPT are in development and may help overcome some of the barriers to oral TPT. We assessed the acceptability of LAI TPT among healthcare workers (HCWs) in a high burden setting. We surveyed physicians and nurses at TB clinics in the country of Georgia from June–July 2024 using a Unitaid 40-question survey. Questions explored overall preference for LAI versus oral TPT, preferences for frequency of injection administration, and attitudes toward LAI TPT. We compared HCWs’ overall preference for LAI TPT by HCW characteristics and opinions of TPT formulation using prevalence ratios (PR) and 95% confidence intervals (CI). Among 127 HCWs, median age was 57 years (interquartile…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsTuberculosis Research and Epidemiology · HIV, Drug Use, Sexual Risk · Dental Research and COVID-19
